Neither preclinical studies in vivo on heterogeneous patient-derived GBM cells with an unmethylated MGMT promoter nor indeed clinical trials have investigated BTZ in sensitisation schedule for Temozolomide, as we propose in this paper. This evidence concerns the gene MGMT and glioblastoma.